| Age at year of index date, % |
| 22-44 years |
2.4% |
5.5% |
<0.0001 |
| 45-54 years |
7.9% |
7.9% |
| 55-64 years |
14.8% |
12.0% |
| 65-74 years |
45.3% |
37.8% |
| >75 years |
29.6% |
36.8% |
| Sex, % |
| Men |
51.3% |
46.2% |
<0.0001 |
| Index diagnosis, % |
| AMI |
21.1% |
11.9% |
<0.0001 |
| Unstable angina |
11.4% |
5.9% |
<0.0001 |
| Hemorrhage |
1.3% |
2.1% |
<0.0001 |
| Stroke |
28.8% |
27.6% |
<0.0001 |
| Transient cerebral ischemia |
10.6% |
10.4% |
0.0558 |
| Cerebrovascular disease |
11.7% |
16.4% |
<0.0001 |
| Atherosclerosis |
7.4% |
8.7% |
<0.0001 |
| Peripheral vascular disease |
25.6% |
32.0% |
<0.0001 |
| Arterial embolism |
0.5% |
0.4% |
0.0438 |
| Arterial disorder |
0.9% |
0.9% |
0.3029 |
| CABG |
3.2% |
0.5% |
<0.0001 |
| Coronary angioplasty |
9.8% |
2.0% |
<0.0001 |
| Revascularization surgery |
0.03% |
0.01% |
<0.0001 |
| Peripheral bypass |
0.16% |
0.17% |
0.3844 |
| Race, % |
| White |
70.0% |
68.9% |
<0.0001 |
| Black |
10.4% |
9.2% |
| Asian |
0.5% |
0.4% |
| Hispanic |
1.8% |
1.3% |
| Unknown |
17.4% |
20.2% |
| Region, % |
| Midwest |
23.5% |
29.1% |
<0.0001 |
| Northeast |
1.8% |
2.3% |
| South |
64.5% |
59.2% |
| West |
9.1% |
8.7% |
| Unknown |
1.2% |
0.7% |
| Health plan, % |
| Medicare |
85.8% |
83.5% |
<0.0001 |
| Medicaid |
0.4% |
0.4% |
| HMO |
3.8% |
4.0% |
| POS |
2.8% |
3.1% |
| PPO |
5.7% |
5.6% |
| Other plan |
1.6% |
3.4% |
| Prior utilization (6 months) |
| Hospital admission, % |
10.1% |
12.9% |
<0.0001 |
| Medical costs, US $, mean (SD) |
1864 (4253) |
2257 (5491) |
<0.0001 |
| Inpatient costs, US $, mean (SD) |
1408 (8084) |
2170 (12 457) |
<0.0001 |
| Pharmacy costs, US $, mean (SD) |
667 (1477) |
651 (1898) |
0.0326 |
| Total costs, US $, mean (SD) |
3939 (10 202) |
5079 (14 754) |
<0.0001 |
| LDL values at baseline in subgroup (n=49 224) |
| Newly eligible secondary prevention patients |
n=14 381 |
n=34 843 |
|
| <101 mg/dL |
30.6% |
45.3% |
<0.0001 |
| 101-130 mg/dL |
34.5% |
35.3% |
| ATP III eligible secondary prevention patients |
|
|
| 131-160 mg/dL |
23.8% |
14.8% |
| >160 mg/dL |
11.1% |
4.6% |